Pan H - Search Results

1

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X, Hu Y, Liu X, Jiang C, Li J, Yang M, Song Y, Wang X, Gao Q, Zhu F. Zhang Y, et al. Among authors: pan h. Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17. Lancet Infect Dis. 2021. PMID: 33217362 Free PMC article. Clinical Trial.

2

Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: a randomized controlled trial in China.

Zhu FC, Zhou W, Pan H, Lu L, Gerez L, Nauta J, Giezeman K, de Bruijn I. Zhu FC, et al. Among authors: pan h. Vaccine. 2008 Aug 18;26(35):4579-84. doi: 10.1016/j.vaccine.2008.05.082. Epub 2008 Jun 17. Vaccine. 2008. PMID: 18602729 Clinical Trial.

3

A novel influenza A (H1N1) vaccine in various age groups.

Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, Zhang XF, Pan HX, Meng FY, Hu YM, Liu WD, Li CG, Li W, Zhang X, Hu JM, Peng WB, Yang BP, Xi P, Wang HQ, Zheng JS. Zhu FC, et al. Among authors: pan hx. N Engl J Med. 2009 Dec 17;361(25):2414-23. doi: 10.1056/NEJMoa0908535. Epub 2009 Oct 21. N Engl J Med. 2009. PMID: 19846844 Free article. Clinical Trial.

4

Booster vaccination against pertussis in Chinese children at six years of age using reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (Boostrix()).

Zhu F, Zhang S, Hou Q, Zhang Y, Xu Y, Ma X, Lu X, Pan H, Chen D, Ramakrishnan G, Zhao R, Tang H, Van Der Meeren O, Bock HL. Zhu F, et al. Among authors: pan h. Hum Vaccin. 2010 Mar 3;6(3):10503. doi: 10.4161/hv.6.3.10503. Epub 2010 Mar 3. Hum Vaccin. 2010. PMID: 20215881

5

Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial.

Zhu FC, Li CG, Pan HX, Zhang YJ, Bi D, Tang HW, Datta S. Zhu FC, et al. Chin J Cancer. 2011 Aug;30(8):559-64. doi: 10.5732/cjc.010.10564. Chin J Cancer. 2011. PMID: 21801604 Free PMC article. Clinical Trial.

6

Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infants.

Zhu FC, Liang ZL, Meng FY, Zeng Y, Mao QY, Chu K, Song XF, Yao X, Li JX, Ji H, Zhang YJ, Li L, Pan HX, Xu K, Dai WM, Zhang WW, Deng F, Wang H, Wang JZ. Zhu FC, et al. Among authors: pan hx. PLoS One. 2012;7(5):e37206. doi: 10.1371/journal.pone.0037206. Epub 2012 May 25. PLoS One. 2012. PMID: 22662137 Free PMC article.

7

Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults.

Pan HX, Zeng Y, Song XF, Zhang YJ, Xu K, Liang ZL, Zhu FC. Pan HX, et al. Vaccine. 2014 Jun 17;32(29):3706-12. doi: 10.1016/j.vaccine.2014.02.094. Epub 2014 Mar 27. Vaccine. 2014. PMID: 24681228 Clinical Trial.

8

The immunogenicity in healthy infants and efficiency to prevent mother to child transmission of Hepatitis B virus of a 10μg recombinant yeast-derived Hepatitis B vaccine (Hep-KSC).

Zhu FC, Sun KX, Pan HX, Yang ZH, Lu Y, Liang ZL, Liang XF, Wang FZ, Zeng Y, Li J. Zhu FC, et al. Vaccine. 2016 May 23;34(24):2656-62. doi: 10.1016/j.vaccine.2016.04.042. Epub 2016 Apr 23. Vaccine. 2016. PMID: 27113166 Clinical Trial.

9

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.

Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W. Zhu FC, et al. Lancet. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20. Lancet. 2020. PMID: 32702299 Free PMC article. Clinical Trial.

10

Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.

Jin P, Li J, Pan H, Wu Y, Zhu F. Jin P, et al. Among authors: pan h. Signal Transduct Target Ther. 2021 Feb 2;6(1):48. doi: 10.1038/s41392-021-00481-y. Signal Transduct Target Ther. 2021. PMID: 33531462 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9,349 results

Search Page